Year All20232022202120202019201820172016201520142013201220112010200920082007200620052004200320022001200019991998 BioCryst to Present New ORLADEYO® (berotralstat) Data at 2023 European Academy of Allergy and Clinical Immunology Congress May 31, 2023 Read More BioCryst Announces Approval of ORLADEYO® (berotralstat) by the Public Health Institute of Chile May 22, 2023 Read More BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) May 04, 2023 Read More BioCryst Reports First Quarter 2023 Financial Results and Provides Business Update May 03, 2023 Read More BioCryst Presents New Long-term Data Demonstrating Consistently High Attack-free Status Among Hereditary Angioedema Patients with ORLADEYO® (berotralstat) Apr 27, 2023 Read More BioCryst to Report First Quarter 2023 Financial Results on May 3 Apr 19, 2023 Read More BioCryst Refinances Existing Debt with $450 Million Financing Commitment from Pharmakon Apr 18, 2023 Read More BioCryst to Present at Upcoming Investor Conferences Apr 12, 2023 Read More BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Apr 04, 2023 Read More BioCryst Appoints Dr. Nancy Hutson as Chair of the Board Mar 31, 2023 Read More
BioCryst to Present New ORLADEYO® (berotralstat) Data at 2023 European Academy of Allergy and Clinical Immunology Congress May 31, 2023 Read More
BioCryst Announces Approval of ORLADEYO® (berotralstat) by the Public Health Institute of Chile May 22, 2023 Read More
BioCryst Reports First Quarter 2023 Financial Results and Provides Business Update May 03, 2023 Read More
BioCryst Presents New Long-term Data Demonstrating Consistently High Attack-free Status Among Hereditary Angioedema Patients with ORLADEYO® (berotralstat) Apr 27, 2023 Read More
BioCryst Refinances Existing Debt with $450 Million Financing Commitment from Pharmakon Apr 18, 2023 Read More